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N -Methyl-d-aspartate (NMDA) receptors play a variety of physiologic roles and their proper
signaling is essential for cellular homeostasis. Any disruption in this pathway, leading to
either enhanced or decreased activity, may result in the manifestation of neuropsychiatric
pathologies such as schizophrenia, mood disorders, substance induced psychosis, Hunting-
ton’s disease, Alzheimer’s disease, and neuropsychiatric systemic lupus erythematosus.
Here, we explore the notion that the overlap in activity of at least one biochemical pathway,
the NMDA receptor pathway, may be the link to understanding the overlap in psychotic
symptoms between diseases. This review intends to present a broad overview of those
neuropsychiatric disorders for which alternations in NMDA receptor activity is prominent
thus suggesting that continued direction of pharmaceutical intervention to this pathway
may present a viable option for managing symptoms.
Keywords: NMDA, psychiatry, schizophrenia, mood disorders, substance induced psychosis, Huntington’s disease,
Alzheimer’s disease, neuropsychiatric systemic lupus erythematosus
INTRODUCTION
Diagnosis of psychiatric disorders is done clinically by focusing
on observable symptoms and behaviors rather than on under-
lying psychodynamic processes or on the results of laboratory
or imaging testing. Understanding the descriptive symptoms for
mental disorders is vital in order to properly diagnose each psy-
chiatric disease. The instruments most commonly used to diag-
nose and categorize mental illnesses, the Diagnostic and Statis-
tical Manual of Mental Disorders (DSM-IV-TR) and the World
Health Organization’s International Statistical Classification of
diseases and Related Health Problems (ICD-10), focus on objec-
tive observations, without offering any discussion on the eti-
ologies for these diseases. From a molecular, biochemical, and
ultimately therapeutic perspective, it is equally as essential to
characterize the role of various receptors, ligands, and neuro-
transmitters that when modified alter the manifestation of these
symptoms.
Psychotic symptoms can be present in primary psychiatric
disorders (schizophrenia, schizoaffective disorder, mood disor-
ders, substance intoxication) and in psychiatric disorders that
occur due to a medical condition such as Huntington’s disease
(HD), Alzheimer’s disease (AD), and systemic lupus erythemato-
sus (SLE). Several neurotransmitters have been linked to the
development of psychotic symptoms, with dopamine and sero-
tonin being the most widely studied due to the treatment effect of
Abbreviations: AA, arachidonic acid; Aβ, amyloid beta; AD, Alzheimer’s disease;
AMPA, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; BPAD, bipolar
affective disorder; CONSIST, Cognitive and Negative Symptoms in Schizophrenia
Trial; DSM, Diagnostic and Statistical Manual of Mental Disorders; DSM-IV-TR,
Diagnostic and Statistical Manual of Mental Disorders, fourth-edition, text-revision;
GABA, in γ-aminobutyric acid; HD, Huntington’s disease; NMDA, N -Methyl-d-
aspartate; SIP, substance induced psychosis; NPSLE, neuropsychiatric systemic lupus
erythematosus; SLE, systemic lupus erythematosus.
blocking certain subtypes of these receptors with antipsychotics.
Unfortunately, long-term treatment with typical or atypical
antipsychotics is limited due to side effects profile and high rates of
discontinuation (Lieberman et al., 2005). N -Methyl-d-aspartate
(NMDA) receptors have also been implicated in the develop-
ment of psychotic symptoms and are a potential target for the
development of novel treatments in the future.
NMDA RECEPTORS IN NEUROPSYCHIATRIC DISORDERS
N -Methyl-d-aspartate receptors are a class of glutamate recep-
tor that when activated, mediate excitatory neurotransmission
via passage of non-selective cations, including Ca2+, through the
channel. They are abundantly and ubiquitously located through-
out the brain and are understood to play a key role in synaptic
plasticity and memory function (Stephenson et al., 2008; Li and
Tsien, 2009). They are activated by binding the co-agonists gluta-
mate and glycine, in addition to exposure to a positive change in
membrane potential across the cell. Functional NMDA receptor
heterotetramers are generally formed through a “dimer of dimers”
mechanism and are conventionally made up of two glycine binding
NR1 subunits and two glutamate binding NR2 subunits (Figure 1)
(Dongen, 2009). While the NR1 subunit is considered essential to
the formation of the complex, data indicates that the NR2 sub-
units may be interchangeable with either one or two NR3 subunits
(Schuler et al., 2008).
The NMDA receptor is known to play an integral role in
the regulation of signal transduction in multiple regions of the
brain. Accordingly, any homeostatic dysfunction of NMDA recep-
tor activity has the potential to result in a variety of pathologies.
Previous authors have found a particularly high concentration of
post-synaptic NMDA receptors in limbic structures (Kretschmer,
1999; Tsapakis and Travis, 2002), which is of uttermost importance
in the pathogenesis of many psychiatric disorders.
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FIGURE 1 | Schematic representation of a typical NMDA receptor. The
NMDA contains four subunits, two glycine binding NR1 subunits and two
glutamate binding NR2 subunits, and allows for cationic influx from the
synaptic cleft into the cell.
Elucidation of the structural and mechanistic properties of
NMDA receptors suggests a potential widespread use as a target
for pharmacological intervention. Structurally, NMDA receptors
provide a number of potentially viable sites for drug interaction.
Initially, efforts focused on the development of broad-spectrum
antagonists and ion channel blockers. However, more recent sub-
type selective targeting and strategic drug development aimed at
these sites has resulted in the production of a variety of NMDA
receptor agonists and antagonists that better address disease con-
ditions ranging from mental disorders to pain management (Kemp
and McKernan, 2002; Paoletti and Neyton, 2007).
N -Methyl-d-aspartate receptor antagonists describe a cate-
gory of compounds that functionally inhibit or deactivate NMDA
receptor activity. They can act broadly or specifically at vari-
ous sites on the NMDA receptor including the agonist binding
domains, allosteric sites, and the ion channel pore. This category
of compounds has a potential use in any disease that results from
glutamate-induced excitotoxicity ranging from cerebral ischemia
and epilepsy to neurodegenerative disorders and neuropathic pain.
More recent developments focus on subunit specific compounds,
including NR2B-selective antagonists, and have resulted in mini-
mization of side effects with improved therapeutic efficacy (Kemp
and McKernan, 2002; Gogas, 2006; Paoletti and Neyton, 2007).
NMDA receptor agonists, on the other hand, refer to the cate-
gory of NMDA receptor targeted compounds that can enhance
receptor activity. It is interesting to note, that some mental dis-
orders can be treated with both NMDA receptor antagonists and
agonists. These biphasic disorders in regards to NMDA receptor
activity may require customized treatment protocols depending
on the stage of the disease.
This review specifically focuses on neuropsychiatric disorders
that manifest with psychotic symptoms and have the molecu-
lar commonality of NDMA receptor activity dysfunction. Here,
we present a broad overview of the alterations in NMDA recep-
tor activity in schizophrenia, bipolar disorder, HD, AD, substance
induced psychosis, and neuropsychiatric systemic lupus erythe-
matosus (NPSLE). We further emphasize the importance of con-
tinued pharmaceutical attention on this pathway as a target for the
development of safer and more effective therapies.
SCHIZOPHRENIA
Schizophrenia is a psychotic disorder characterized by abnormal-
ities in thought processing and content, presence of delusions
and/or hallucinations as well as the presence of negative symp-
toms. Schizophrenia is a worldwide public health issue that affects
approximately 1% of the adult population. While some symp-
toms and molecular pathways overlap with other related disorders
including bipolar disorder, schizophrenia is unique in its precise
presentation of positive, negative, and cognitive symptoms. For
many years the dopamine hypothesis prevailed to explain symp-
toms associated with schizophrenia (Meltzer and Stahl, 1976).
Thus, conventional antipsychotic drugs used to treat these patients
would act by interfering with and inhibiting dopamine neuro-
transmission. While individuals using those drugs experienced
significantly reduced positive psychotic symptoms, the effects were
not optimal and often resulted in adverse side effects (Levin-
son, 1991; Fleischhacker, 1995). More recent elucidation of other
neurotransmitter pathways involved in the manifestation of schiz-
ophrenia, such as serotonin and glutamate has provided novel
treatment targets aimed at more effectively inhibiting both posi-
tive and negative symptoms (Fitzgerald et al., 1995; Iqbal and van
Praag, 1995; Lindenmayer, 1995). Atypical antipsychotics act by
blocking of serotonin type 2 and D2 receptors, initially, these med-
ications were thought to be superior to typical antipsychotics due
to less extrapyramidal side effects, however, recent evidence shows
that there is also high discontinuation rate of atypical antipsy-
chotics (Lieberman et al., 2005). Low treatment adherence has
led investigators to study different and novel mechanisms for
the development of novel medications for the management of
psychosis.
Initial data in support of a more novel glutamate hypofunc-
tion hypothesis of schizophrenia arose from reports of low cere-
brospinal fluid glutamate levels in patients with schizophrenia
(Kim et al., 1980). Further studies corroborate this theory and indi-
cate that administration of NMDA receptor antagonists including
phencyclidine (PCP) and ketamine to patients with schizophrenia
resulted in worsening of psychotic symptoms (Luby et al., 1959;
Lahti et al., 1995; Gilmour et al., 2012). Additional studies reveal
that administration of similar antagonists to healthy patients repli-
cates symptoms of schizophrenia including positive, negative, and
cognitive symptoms (Krystal et al., 1994; Gilmour et al., 2012).
Building on these data, more recent pharmacological
approaches aimed at treating schizophrenia focus on the use of
NMDA receptor agonists (Kemp and McKernan, 2002). How-
ever, direct activation of the receptor and reported excitotoxi-
city suggests the need to more specifically explore the glycine
binding site as a potentially safer indirect target for treating
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glutamate hypofunction disorders (Lechner, 2006; Paoletti and
Neyton, 2007). A number of studies are currently exploring this
mechanism as a means of treating symptoms with minimal side
effects. Both naturally occurring and synthetic glycine agonists
including glycine, d-serine, and d-cycloserine are showing great
promise for the treatment of positive and negative symptoms of
schizophrenia (Coyle et al., 2003; Millan, 2005; Long et al., 2006).
Following a similar mechanistic approach of indirectly targeting
the glycine binding site, Glycine transport 1 (GLY-T1) inhibitors
are being explored in order to modulate NMDA receptor function.
The GLY-T1 reuptake pump functions to remove excess glycine in
the synaptic cleft and thus inhibitors are being actively explored
to increase glycine at the synapse. Animal data from transgenic
mice suggest that the GLY-T1 inhibitor SSR103800 shows efficacy,
decreased side effects, and suggests a use for GLY-T1 inhibitor as an
adjunct to conventional therapy for schizophrenia (Boulay et al.,
2010).
One of the largest trials performed so far studying the effect
of increased glutamate transmission is the Cognitive and Neg-
ative Symptoms in Schizophrenia Trial (CONSIST) (Buchanan
et al., 2007). The trial’s primary aim was to determine if co-
administration of glycine (co-transmitter with glutamate at the
NMDA receptor) or d-cycloserine (partial agonist at NMDA
receptor) was associated with an improvement in cognitive impair-
ment or in the negative symptoms of schizophrenia. During the
trial, there was no improvement in the above mentioned symp-
toms with the experimental treatments. However, despite negative
findings in this trial, there is clear evidence that NMDA recep-
tor dysfunction is implicated in schizophrenia, and it is still an
important research area for the development of future treatments.
Additional clinical evidence demonstrates that the GLY-T1
inhibitor Org 25935 has been explored for its antipsychotic prop-
erties. Preliminary human data indicate that it can effectively
counteract the effects of the NMDA receptor antagonist, ket-
amine (D’Souza et al., 2012). Promising Phase II clinical data
corroborate these results and further suggest that the GLY-T1
inhibitor RG1678 was a safe and effective compound for treating
the negative symptoms of schizophrenia (Pinard et al., 2010).
The dopamine hypothesis and the glutamate hypofunction
hypothesis of schizophrenia each separately explain specific
aspects of the disease condition. However, some researchers argue
that focusing on only one molecular pathway to characterize the
complicated etiology of the disease is likely to narrow our under-
standing. In fact, some additional theories provide evidence that
hypofunction of NMDA receptors results in dopaminergic abnor-
malities. Interestingly, this synergy between the two pathways best
explains the positive, negative, and cognitive symptoms associated
with the disease (Schwartz et al., 2012). Still, despite not agreeing
on a molecular mechanism to explain the manifestation of schizo-
phrenia, scientists do agree that NMDA receptor dysfunction plays
an integral role and should continue to be studied as a therapeutic
target.
MOOD DISORDERS
Mood is described as the internal feeling tone that influences
the way an individual perceives himself and the environment.
The most widely studied mood disorders are major depressive
disorder, and bipolar affective disorder (BPAD), the latter one
is characterized by alternation between manic and depressive
episodes. Psychotic symptoms can be present in severe episodes of
depression, mania, or during mixed states (Stahl, 2008). Mood dis-
orders were initially thought to be caused by alterations in the levels
of norepinephrine and serotonin, but this theory has not been able
to completely explain the cause of this complex illness, this is evi-
denced by the results from a large-randomized clinical trial where
only two-thirds of the patients who were treated with several treat-
ment courses of different antidepressants experienced remission
of their depression (Gaynes et al., 2008). Other theories include
the alteration of hormonal regulation (hypothalamic-pituitary
and thyroid axis dysfunction), alterations in γ-aminobutyric acid
(GABA) receptors, and alterations in the arachidonic acid pathway
and NMDA receptors.
The arachidonic acid (AA) hypothesis of BPAD represents a well-
studied mechanism used to explain the pathophysiology of the
disease. Support for this hypothesis gained popularity based on
data showing that BPAD is associated with an upregulation in the
AA cascade. These data were validated by reports that inhibitors
of this cascade, including lithium, were successful mood stabilizers
(Rapoport and Bosetti, 2002).
Similar to other mental disorders with psychotic manifesta-
tions, NMDA receptor activity seems to be intimately involved
in the complicated web of pathways leading to the pathogen-
esis of mood disorders. The NMDA receptor antagonist, keta-
mine, has been shown to rapidly improve symptoms of depres-
sion (Zarate et al., 2006). Evidence from rat models has shown
that the rapid improvement in depressive symptoms observed
with ketamine is caused by an increase in the activation of
the mammalian target of rapamycin (mTOR) pathway causing
an increase in the number of neuronal synapses – opposite to
changes seen during stress (Li et al., 2010). Other authors have
described that ketamine also produces a disinhibition of GABAer-
gic neurons, leading to increased presynaptic levels of gluta-
mate; which then interacts with α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid (AMPA) receptors, as the NMDA recep-
tors are blocked by ketamine. This increased ratio of AMPA to
NMDA activation and may be implicated in the antidepressant
effects of ketamine (Sanacora et al., 2008; Andreasen et al., 2013).
Reports indicate there are elevated levels of glutamate in the
left dorsolateral prefrontal cortex of adults with BPAD during the
manic phase (Michael et al., 2003). More recent studies show that
treatment with the NMDA receptor antagonist, MK-801, results in
inhibition of the downstream AA pathway (Basselin et al., 2006).
In addition, gene linkage analysis confirmed a role specifically for
the NR2B subunit of the NMDA receptor in BPAD (Martucci et al.,
2006). Together, these studies suggest that NMDA receptor activ-
ity plays a critical role in mood disorders likely through the in AA
pathway.
HUNTINGTON’S DISEASE
Huntington’s disease is a progressive genetic neurodegenerative
disorder that results in decreased muscle coordination and cog-
nitive ability. It is typically diagnosed between 30 and 40 years of
age and often results in death within 15–20 years. In many cases,
patients also present with psychiatric symptoms including some
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similar to those observed in patients with schizophrenia. On a
molecular level, the underlying cause of HD is considered to be
disruptions in the gene that encode the protein huntingtin, whose
altered function ultimately leads to selective neuronal cell death
(Gusella et al., 1983).
Some data suggest that the formation of nuclear protein aggre-
gates plays a role in neuronal cell death associated with the disease
(Carmichael et al., 2000). Others explore a variety of also likely
contributing pathways including oxidative stress and impaired
mitochondrial function (Davies and Ramsden, 2001). However,
considering the focus of this review and the potential for manifes-
tation of psychotic symptoms in HD, it is interesting to specifically
note the role of the NMDA receptor pathway.
Early animal studies indicate that injections with kainic or
quinolinic acids produce lesions similar to those observed in HD
thus promoting the idea that NMDA receptor-mediated exci-
totoxicity may also contribute to the etiology of the disease
(Coyle and Schwarcz, 1976; Beal et al., 1986). Related studies
corroborate these early findings and report hyperactive NMDA
receptors present in transgenic HD mice (Levine et al., 1999).
Prolonged receptor activation results in excitotoxicity and cell
death characteristic of many neurodegenerative disorders includ-
ing HD. Further elucidation of this pathway explores a role for
post-synaptic density protein 95 (PSD-95), a well-characterized
scaffolding protein that binds to multiple cytoplasmic proteins
including normal huntingtin and separately to the NR2 sub-
unit of NMDA receptors. Once bound it causes clustering of
receptors in the post-synaptic membrane and results in physio-
logic inhibition of NMDA receptor activity. In the case of HD,
the presence of mutant huntingtin protein results in a disrup-
tion of PSD-95 binding to NMDA receptors, receptor hyper-
sensitivity and resulting excitotoxicity, and ultimately increased
neuronal cell death consistent with HD (Davies and Ramsden,
2001; Sun et al., 2001). Similar to schizophrenia and other com-
plicated mental disorders, data point to the possibility of mul-
tiple and potentially parallel pathways giving rise to the vari-
ety of documented symptoms in HD. Nonetheless, the NMDA
receptor pathway still remains a primary target for therapeutic
intervention.
ALZHEIMER’S DISEASE
Alzheimer’s disease describes a type of dementia that results in
serious and progressive cognitive impairment. Symptoms range
from commonly observed memory loss to psychotic manifesta-
tions including delusions. Currently, clinicians diagnose patients
based on DSM-outlined criteria; however, a definitive diagnosis
can only be made post-mortem.
For many years, the amyloid hypothesis of AD was the dominat-
ing model thought to explain the pathophysiology of the disorder.
This hypothesis gained early popularity based on data that iden-
tified amyloid β-peptide (Aβ) as an integral component in the
plaques observed post-mortem in AD (Masters et al., 1985). Addi-
tional reports confirm the central role of the Aβ protein and
suggest that its accumulation initiates downstream diseases symp-
toms and molecular manifestations including alteration in the tau
protein and the formation of characteristic neurofibrillary tangles
(Hardy et al., 1998; Hardy and Selkoe, 2002).
As mentioned above,NMDA receptors are well-studied for their
crucial role in learning and memory, key areas that are affected in
the manifestation of AD. Similar to other mental disorders, AD
is likely the result of dysfunction in multiple neurotransmitter
pathways. In fact, data suggest an overlap in pathways related to
NMDA receptor activation and production of characteristic bio-
chemical and symptomatic changes that occur in AD. However,
the exact nature of that overlap is not yet determined. Consis-
tent with the idea that accumulation of Aβ protein initiates the
pathological cascade, some studies suggest that the NMDA recep-
tor may function indirectly as a receptor for the Aβ protein (Cisse
et al., 2011; Malinow, 2012). A recent report from Cisse et al.,
indicates that the Aβ protein binds directly to the tyrosine kinase
receptor, EphB2, a known regulator of NMDA receptor function
(Cisse et al., 2011; Nolt et al., 2011). This results in degradation of
EphB2 and a downstream reduction in NMDA receptor-mediated
long term potentiation (Cisse et al., 2011). Other studies suggest
that enhanced NMDA receptor activity results in increased pro-
cessing of the amyloid beta precursor protein thus producing an
increase in the AD characteristic Aβ protein. This in turn results in
a decrease in excitatory synaptic transmission and may contribute
to cognitive effects observed in early stages of AD (Gordon-Krajcer
et al., 2002; Butterfield and Pocernich, 2003). With regards to the
glutamatergic pathway, AD is unique in that receptor dysfunction
is dependent on stage of the disease. In contrast with theories
describing the pathogenesis of early stage AD, late stage pathogen-
esis is thought to be attributed to loss of NMDA receptors and
resulting hypoactivity (Butterfield and Pocernich, 2003).
Precise mechanism aside, researchers agree that in conjunction
with Aβ protein accumulation, the NMDA receptor pathway is
integral in the manifestation of AD pathophysiology. Thus data
point to the notion of a strategic combination therapy regimen to
most effectively treat the condition.
SUBSTANCE INDUCED PSYCHOSIS
Substance induced psychosis (SIP) disorder represents another
defined mental disorder that results in delusions or hallucinations
that are linked to use or withdrawal from a variety of defined
compounds. Interestingly, NMDA receptor antagonists PCP and
ketamine, previously shown to produce an elevation of psychotic
symptoms in patients with schizophrenia, are among the drugs
reported to result in SIP (Luby et al., 1959; Lahti et al., 1995;
Gilmour et al., 2012). Furthermore, there is evidence of potential
for conversion from SIP to the more clearly defined psychotic dis-
order, schizophrenia (Rabe-Jablonska et al., 2012; Niemi-Pynttari
et al., 2013). Although, the data in this space are mostly descriptive
and the broad description of SIP gives rise to a poorly defined
molecular mechanism, the likely role of NMDA receptors in the
psychotic manifestation of this disease should not be left unnoted.
NEUROPSYCHIATRIC SYSTEMIC LUPUS ERYTHEMATOSUS
Systemic lupus erythematosus is an autoimmune disorder that
results in inflammation and threatens tissue damage to a num-
ber of different organ systems including the skin, heart, joints,
lungs, and nervous system. Neuropsychiatric systemic lupus
erythematosus is a poorly understood yet prevalent complication
of SLE. It results when SLE specifically affects the central or
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Table 1 | Select NMDA receptor-targeted drugs used in clinical trials
for the treatment of mental disorders.
Drug Primary disease
target
Mechanism of action
D-Serine Schizophrenia NMDA receptor glycine site
agonist
Sarcosine Schizophrenia NMDA receptor glycine site
agonist
D-Amino acid
oxidase inhibitor
Schizophrenia NMDA enhancing agent via
inhibition of the degradation
d-serine levels
Clozapine Schizophrenia NMDA receptor enhancer
Memantine Bipolar disorder NMDA receptor antagonist
Memantine Huntington’s disease NMDA receptor antagonist
Amantadine Huntington’s disease NMDA receptor antagonist
Neramexane Alzheimer’s disease NMDA receptor antagonist
Memantine Alzheimer’s disease NMDA receptor antagonist
D-Amino acid
oxidase inhibitor-B
Alzheimer’s disease NMDA enhancing agent
Memantine Neuropsychiatric
systemic lupus
erythematosus
NMDA receptor antagonist
This table presents select drugs that, at minimum, have been approved for initial
clinical testing (NLM, 2013). This approval provides evidence of the important
of the NMDA receptor pathway in the potential treatment of various mental
disorders.
peripheral nervous systems and patients manifest additional neu-
rological symptoms such as psychosis, mood disorders, or cogni-
tive dysfunction (Popescu and Kao, 2011). While the mechanism
of NMDA receptor activity involvement is unique compared to
the previously mentioned conditions, it is important to mention
as it represents additional, albeit less clearly defined, evidence of an
integral role for the NMDA receptor pathway in the pathogenesis
of mental disorders.
Autoantibodies represent a type of antibody specifically tar-
geted to endogenous proteins in an individual. They are under-
stood to cause many of the symptoms associated with autoimmune
disorders, including SLE. Previous data indicate that the cog-
nitive manifestations of NPSLE may be related to medication
and cardiovascular disease. However, additional data suggest that
autoantibodies directed against various NMDA receptor subunits
may also play a role in pathogenesis.
Studies show that NMDA receptor autoantibodies are preva-
lent in the manifestation of both mood symptoms and psychotic
behaviors observed in patients with NPSLE (Mak et al., 2009).
More specifically, autoantibodies to the NR2A and NR2B subunits
of the NMDA receptor mediate neuronal death in vitro follow-
ing breakdown of the blood brain barrier (Shefner et al., 1991;
Katz et al., 1994; Gaynor et al., 1997; Kowal et al., 2004). Interest-
ingly, the NMDA receptor antagonist memantine has been show
to protect neurons from autoantibody-mediated cell injury, thus
indicating that these autoantibodies may be acting as functional
agonists (Lipton and Rosenberg, 1994; Kowal et al., 2004, 2006).
Translating these results to human clinical trials, however, did not
show similar efficacy (Petri et al., 2011). While these data may
initially seem discouraging, there were some reported study lim-
itations, including the use of physician confirmed, self-reported
cognitive impairment. The authors indicate that memantine may
still ultimately provide a therapeutic benefit in preventing the
worsening of cognitive symptoms. Together, these data suggest
that NMDA receptor antagonists represent a much underrated
potential therapy for NPSLE.
CONCLUSION
The role of the NMDA receptor pathway in a broad range of dis-
eases and disorders is well established. However, how that “role”
plays into the larger picture of disease manifestation is not entirely
clear. Specifically, in the case of complicated mental disorders
that manifest in a variety of symptoms including psychosis, the
NMDA receptor pathway comes into play. Alterations in its activity
lead to either hypofunction or hyperfunction and related exci-
totoxicity. To further complicate the matter, changes in NMDA
receptor activity may be dependent on the stage of disease. For
example, as indicated above, symptoms of AD can be initially
attributed to glutamate-induced excitotoxicity. Late stage patho-
genesis however, is thought to be a result, in part, of NMDA
receptor hypoactivity.
Table 1 presents select NMDA receptor-targeted drugs that
have been used as a monotherapy in clinical trials to allevi-
ate symptoms of schizophrenia, BPAD, HD, AD, and NPSLE.
Still, many other drugs and various drug combinations are also
being explored in preclinical studies. While research has not
yet clearly elucidated how these changes in receptor activity tie
into the overlapping symptoms between mental disorders, we
can be certain that maintaining receptor homeostasis is inte-
gral for symptom management. Combination therapy directed
at selective NMDA receptor antagonists and enhancers in addi-
tion to drugs that target other disease-specific pathways may
be the key to controlling the symptoms of psychotic disorders.
However, more thorough molecular comparisons between the
various mental disorders with psychotic manifestations is still
needed.
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